Taken together, these data support our hypothesis #1 (KRAS-mutated adenomyotic clones are less sensitive to DNG treatment) rather than hypothesis #2 (DNG drives KRAS mutations in adenomyosis patients). Here, KRAS is linked to adenomyosis.